Outcomes of high-dose-rate interstitial brachytherapy in the treatment of locally advanced cervical cancer: long-term results.
- 2013-03
- International Journal of Radiation Oncology*Biology*Physics 85(3)
- M. Pinn-Bingham
- A. Puthawala
- A. Syed
- Anil K. Sharma
- P. Disaia
- M. Berman
- K. Tewari
- Leslie
- Randall-Whitis
- U. Mahmood
- N. Ramsinghani
- J. Kuo
- Wen‐Pin Chen
- C. McLaren
- PubMed: 22763030
- DOI: 10.1016/j.ijrobp.2012.05.033
Study Design
- Type
- Observational
- Sample size
- n = 116
- Population
- Patients with locally advanced cervical cancer
- Methods
- Retrospective review
Abstract
Purpose: The purpose of this study was to determine locoregional control (LRC), disease-free survival (DFS), and toxicity of high-dose-rate interstitial brachytherapy (HDR-ISBT) in the treatment of locally advanced cervical cancer.
Methods and materials: Between March 1996 and May 2009, 116 patients with cervical cancer were treated. Of these, 106 (91%) patients had advanced disease (International Federation of Gynecology and Obstetrics stage IIB-IVA). Ten patients had stage IB, 48 had stage II, 51 had stage III, and 7 had stage IVA disease. All patients were treated with a combination of external beam radiation therapy (EBRT) to the pelvis (5040 cGy) and 2 applications of HDR-ISBT to a dose of 3600 cGy to the implanted volume. Sixty-one percent of patients also received interstitial hyperthermia, and 94 (81%) patients received chemotherapy.
Results: Clinical LRC was achieved in 99 (85.3%) patients. Three-year DFS rates were 59%, 67%, 71%, and 57% for patients with stage IB, II, III, and IVA disease, respectively. The 5-year DFS and overall survival rates for the entire group were 60% and 44%, respectively. Acute and late toxicities were within acceptable limits.
Conclusions: Locally advanced cervical cancer patients for whom intracavitary BT is unsuitable can achieve excellent LRC and OS with a combination of EBRT and HDR-ISBT.